ENTRY       D10293            Mixture   Drug
NAME        Carbidopa, levodopa and entacapone;
            Stalevo (TN)
PRODUCT     STALEVO (Almatica Pharma LLC)
  GENERIC   CARBIDOPA, LEVODOPA AND ENTACAPONE (Rising Pharma Holdings)
            CARBIDOPA, LEVODOPA AND ENTACAPONE (Wockhardt USA LLC.)
            CARBIDOPA, LEVODOPA, AND ENTACAPONE (Sandoz)
COMPONENT   Carbidopa hydrate [DR:D00558], Levodopa [DR:D00059], Entacapone [DR:D00781]
CLASS       Neuropsychiatric agent
             DG01967  Antiparkinson agent
              DG02909  COMT inhibitor
            Metabolizing enzyme inhibitor
             DG01643  CYP2C9 inhibitor
REMARK      Therapeutic category: 1169
            ATC code: N04BA03
            Product: D10293<JP/US>
EFFICACY    Antiparkinsonian
  DISEASE   Parkinson disease [DS:H00057]
COMMENT     Entacapone is an inhibitor of COMT and CYP2C9.
INTERACTION CYP inhibition: CYP2C9 [HSA:1559]
            Enzyme inhibition: COMT [HSA:1312]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N04 ANTI-PARKINSON DRUGS
               N04B DOPAMINERGIC AGENTS
                N04BA Dopa and dopa derivatives
                 N04BA03 Levodopa, decarboxylase inhibitor and COMT inhibitor
                  D10293  Carbidopa, levodopa and entacapone &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antiparkinson Agents
              Antiparkinson Agents, Other
               Carbidopa/ Levodopa/ Entacapone
                D10293  Carbidopa, levodopa and entacapone
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              11  Agents affecting central nervous system
               116  Antiparkinsonian agents
                1169  Others
                 D10293  Carbidopa, levodopa and entacapone
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG01967  Antiparkinson agent
               DG02909  COMT inhibitor
                D10293  Carbidopa, levodopa and entacapone
             Metabolizing enzyme inhibitor
              DG01643  CYP2C9 inhibitor
               D10293  Carbidopa, levodopa and entacapone
            Drug classes [BR:br08332]
             Neuropsychiatric agent
              DG01967  Antiparkinson agent
               D10293  Carbidopa, levodopa and entacapone
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10293
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10293
DBLINKS     PubChem: 163312324
///
